Immunome (IMNM) Total Debt (2020 - 2021)

Immunome (IMNM) posted Total Debt of $500000.0 for Q1 2021, little changed on a QoQ basis from $500000.0 in Q4 2020.

Immunome (IMNM) Total Debt (2020 - 2021) Analysis & Trends

Immunome's Total Debt history runs 2 years deep, the most recent figure standing at $500000.0 for Q1 2021.

  • Quarterly Total Debt changed N/A year-over-year to $500000.0 in Q1 2021, while the trailing twelve-month figure through Mar 2021 was $500000.0 (changed N/A YoY) and the FY2020 annual result came in at $500000.0, changed N/A from the prior year.
  • Total Debt was $500000.0 for Q1 2021 at Immunome, roughly flat from $500000.0 in the prior quarter.
  • Across five years, Total Debt topped out at $500000.0 in Q3 2020 and bottomed at $500000.0 in Q3 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.96 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 959.06 Mn
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 1.99 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Immunome 2.49 Bn 1.91 Bn - -

Historic Data

Download Data
DateValue
Mar 31, 2021 500,000.00
Dec 31, 2020 500,000.00
Sep 30, 2020 500,000.00